---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-139057"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:43:51.458412+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TScan enters $30M upfront collaboration with Amgen to identify Crohn's disease T-cell targets

## Summary
- TScan receives $30M upfront; eligible for over $500M in development and commercial milestone payments.
- Amgen gains exclusive global rights to develop and commercialize therapeutics from discovered targets.
- Amgen holds an option to expand the collaboration to include ulcerative colitis under predefined terms.
- TScan also earns tiered single-digit royalties on net sales from any products developed.

## SEC filing metadata
- accession: 0001193125-23-139057
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/0001193125-23-139057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/d420303d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-139057
- JSON: https://secwatch.observer/filing/0001193125-23-139057.json
- Plain text: https://secwatch.observer/filing/0001193125-23-139057.txt

## Key facts
- Material Agreements
  TScan Therapeutics, Inc. entered into Agreement with Amgen Inc. valued at $30 million (effective 2023-05-08).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Amgen Inc.
  - Value: $30 million
  - Effective: 2023-05-08
  source text: On May 8, 2023, TScan Therapeutics, Inc. (“ TScan ” or the “ Company ”), entered into a Collaboration Agreement (the “ Agreement ”) with Amgen Inc. (“ Amgen ”) to identify antigens recognized by T cells in patients with Crohn’s disease utilizing the Company’s proprietary target discovery platform, TargetScan (“ TargetScan ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1783328/000119312523139057/0001193125-23-139057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.